Experiment Overview
flowchart TD
experiments_non_dopaminergic_n["Non-Dopaminergic Neurotransmitter Degeneration i"]
experiments_non_dopaminergic_n["Experiment"]
experiments_non_dopaminergic_n -->|"related to"| experiments_non_dopaminergic_n
style experiments_non_dopaminergic_n fill:#81c784,stroke:#333,color:#000
experiments_non_dopaminergic_n["Study"]
experiments_non_dopaminergic_n -->|"related to"| experiments_non_dopaminergic_n
style experiments_non_dopaminergic_n fill:#81c784,stroke:#333,color:#000
experiments_non_dopaminergic_n["Code"]
experiments_non_dopaminergic_n -->|"related to"| experiments_non_dopaminergic_n
style experiments_non_dopaminergic_n fill:#81c784,stroke:#333,color:#000
experiments_non_dopaminergic_n["NDNS-PD-001"]
experiments_non_dopaminergic_n -->|"related to"| experiments_non_dopaminergic_n
style experiments_non_dopaminergic_n fill:#81c784,stroke:#333,color:#000
style experiments_non_dopaminergic_n fill:#4fc3f7,stroke:#333,color:#000
Study Code: NDNS-PD-001
Hypothesis: Degeneration of non-dopaminergic neurotransmitter systems (noradrenergic, serotonergic, cholinergic, GABAergic) is an upstream driver of [Parkinson's disease](/diseases/parkinsons-disease) progression, occurring independently of and potentially preceding dopaminergic loss.
Phase: Preclinical + Clinical Translation
Study Design
Phase 1: Basic Research (In vitro)
1.1 Non-Dopaminergic Neuron Vulnerability Assessment
...Experiment Overview
Mermaid diagram (expand to render)
Study Code: NDNS-PD-001
Hypothesis: Degeneration of non-dopaminergic neurotransmitter systems (noradrenergic, serotonergic, cholinergic, GABAergic) is an upstream driver of [Parkinson's disease](/diseases/parkinsons-disease) progression, occurring independently of and potentially preceding dopaminergic loss.
Phase: Preclinical + Clinical Translation
Study Design
Phase 1: Basic Research (In vitro)
1.1 Non-Dopaminergic Neuron Vulnerability Assessment
Objective: Validate selective vulnerability of non-dopaminergic neurons to [alpha-synuclein](/proteins/alpha-synuclein) toxicity
Models:
- iPSC-derived neurons from:
- [PD](/diseases/parkinsons-disease) patients with [LRRK2](/genes/lrrk2) G2019S mutation (n=3)
- PD patients with idiopathic PD (n=3)
- Healthy controls (n=3)
- Cell types: [locus coeruleus](/cell-types/locus-coeruleus) noradrenergic, [dorsal raphe](/brain-regions/dorsal-raphe-nucleus) serotonergic, [pedunculopontine](/cell-types/pedunculopontine-nucleus) cholinergic, cortical GABAergic
Endpoints:
- Neuronal survival after α-syn oligomer exposure (MTT, Live/Dead)
- Neurotransmitter synthesis enzymes (TH, TPH2, ChAT, GAD67)
- Calcium homeostasis (Fura-2 imaging)
- Mitochondrial function (Seahorse XF)
1.2 Neurotransmitter System Interaction Mapping
Objective: Map functional interactions between non-dopaminergic systems
Models:
- Co-culture systems: LC + DRN; PPN + NBM; LC + PPN
- Optogenetic manipulation of each system
Endpoints:
- Neurotransmitter release (norepinephrine, serotonin, acetylcholine, GABA)
- Network activity (multi-electrode array)
- Calcium signaling synchronization
1.3 Alpha-Synuclein Effects on Non-Dopaminergic Systems
Objective: Determine if α-syn pathology directly targets non-dopaminergic nuclei
Models:
- Primary neurons from LC, DRN, PPN
- Exposure to α-syn pre-formed fibrils (PFF)
Endpoints:
- Phosphorylation (pSer129) and aggregation
- Neurotransmitter enzyme expression
- Axonal transport (live cell imaging)
Phase 2: Preclinical (In vivo)
2.1 Non-Dopaminergic System Imaging in PD Models
Objective: Validate non-dopaminergic degeneration in established PD models
Models:
- [Alpha-synuclein](/proteins/alpha-synuclein) transgenic mice (M83, Thy1-α-syn)
- AAV-α-syn injection in rat [LC](/cell-types/locus-coeruleus), [DRN](/brain-regions/dorsal-raphe-nucleus), [PPN](/cell-types/pedunculopontine-nucleus)
- [LRRK2](/genes/lrrk2) G2019S knock-in mice
Endpoints:
- Neurotransmitter levels (HPLC: NE, 5-HT, ACh, GABA)
- Neuron counts (TH, TPH2, ChAT, GAD67 IHC)
- [PET](/diagnostics/pet-imaging) imaging (VMAT2, 5-HT2A, nicotinic ligands)
2.2 Therapeutic Intervention: Multi-Target Approach
Objective: Test combined neurotransmitter modulation
Models:
- AAV-α-syn injected rats with LC, DRN, PPN targeting
- Pharmacological intervention at 3 months post-injection
Interventions:
- Noradrenergic: Atomoxetine (NET inhibitor) 10 mg/kg
- Serotonergic: 5-HT2A antagonist (M100907) 1 mg/kg
- Cholinergic: Donepezil 3 mg/kg
- Combination: All three
Endpoints:
- Motor behavior (cylinder, stepping, gait analysis)
- Non-motor (olfaction, nesting, sucrose preference)
- Neurotransmitter levels
- Neuronal survival
2.3 Neuroprotective Strategy: Early Intervention
Objective: Test if early intervention preserves non-dopaminergic systems
Models:
- M83 mice (starting at 3 months, pre-symptomatic)
Interventions:
- AAV-DREADD expression in LC for chemogenetic activation
- Antioxidant treatment ( Nacetylcysteine 150 mg/kg)
Endpoints:
- Non-dopaminergic neuron survival
- Neurotransmitter levels
- Progression to symptomatic phase
Phase 3: Clinical Translation
3.1 Biomarker Development
Objective: Identify CSF and imaging biomarkers for non-dopaminergic degeneration
Cohorts:
- De novo PD patients (n=50)
- PD with RBD (n=30)
- PD-MCI (n=30)
- Healthy controls (n=30)
Endpoints:
- CSF: 5-HIAA, MHPG, ACh, GABA
- Serum: Neurofilament light chain (NfL)
- PET: VMAT2, 5-HT2A, nicotinic, GABA-A
- MRI: Neuromelanin-sensitive imaging (LC, raphe)
3.2 Non-Dopaminergic Targeted Therapy Trial
Objective: Test multi-target intervention in PD patients
Design: Randomized, double-blind, placebo-controlled
Cohort: Early PD (H&Y 1-2), with non-motor symptoms (n=120)
Interventions (12 weeks):
- Arm 1: Atomoxetine 40mg daily
- Arm 2: Donepezil 10mg daily
- Arm 3: Combination
- Arm 4: Placebo
Endpoints:
- Primary: MDS-UPDRS Part III (motor), Non-motor symptoms (MDS-NMS)
- Secondary: Attention (Stroop), Executive (Trail Making), CSF biomarkers
- Safety: Adverse events, ECG
3.3 Longitudinal Progression Study
Objective: Map non-dopaminergic degeneration trajectory
Cohort: Newly diagnosed PD (n=200), follow 5 years
Endpoints:
- Annual PET imaging (all receptor systems)
- CSF neurotransmitter metabolites
- Clinical assessment (motor and non-motor)
- Progression to dementia, falls
Outcome Measures
Primary Endpoints
| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| Non-dopaminergic neuron survival | IHC (TH, TPH2, ChAT) | 6 months |
| Neurotransmitter levels | HPLC | 6 months |
| Motor behavior | cylinder, stepping | 3, 6 months |
| Non-motor behavior | OFT, nesting | 3, 6 months |
Secondary Endpoints
| Endpoint | Method | Timepoint |
|----------|--------|-----------|
| Network activity | MEA | 2 weeks |
| Biomarkers | CSF/serum | Baseline, 6 months |
| PET imaging | VMAT2, 5-HT2A | Baseline, 6 months |
| Clinical outcomes | MDS-UPDRS | Every 3 months |
Statistical Analysis
- Sample size: Power 80% to detect 30% difference (α=0.05)
- Repeated measures ANOVA for time-course
- Linear mixed models for longitudinal data
- Correction for multiple comparisons (Bonferroni)
Ethical Considerations
- Animal welfare: 3R principles, ARRIVE guidelines
- Human subjects: IRB approval, informed consent
- Vulnerable populations: Careful inclusion criteria for cognitive impairment
Timeline
- Phase 1: 12 months
- Phase 2: 18 months
- Phase 3: 36 months (biomarker) + 24 months (clinical trial)
- Total: 5 years
Budget Estimate
- Phase 1: $500K
- Phase 2: $1.2M
- Phase 3: $3.5M
- Total: $5.2M
References
cholinergic2021, Bohnen NI, et al. Cholinergic deficiency contributes to cognitive impairment in Parkinson's disease. Brain. 2021
gaba2019, Galvan A, et al. GABAergic dysfunction in Parkinson's disease. Neurobiol Dis. 2019
locus2022, Weinshenker D, et al. Locus coeruleus dysfunction in Parkinson's disease. Mov Disord. 2022
rbd2019, Iranzo A, et al. Prodromal Parkinson disease in REM sleep behavior disorder. Ann Neurol. 2019
serotonergic2022, Qiu MH, et al. Serotonergic dysfunction in Parkinson's disease. Mov Disord. 2022
See Also
- [HMGB1 — High Mobility Group Box 1](/wiki/genes-hmgb1) — biomarker_for